| Preview | Issue Date | Title | Author(s) |
| 2013 | A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias | Cortes, J.E.; Kim, D.W.; Pinilla-Ibarz, J.; Le Coutre, P.; Paquette, R.; Chuah, C.; Nicolini, F.E.; Apperley, J.F.; Khoury, H.J.; Talpaz, M.; DiPersio, J.; DeAngelo, D.J.; Abruzzese, E.; Rea, D.; Baccarani, M.; Müller, M.C.; Gambacorti-Passerini, C.; Wong, S.; Lustgarten, S.; Rivera, V.M.; et al. |
| 2013 | Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy | Angelini, S.; Soverini, S.; Ravegnini, G.; Barnett, M.; Turrini, E.; Thornquist, M.; Pane, F.; Hughes, T.; White, D.; Radich, J.; Kim, D.; Saglio, G.; Cilloni, D.; Iacobucci, I.; Perini, G.; Woodman, R.; Cantelli-Forti, G.; Baccarani, M.; Hrelia, P.; Martinelli, G. |
| 2009 | Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet | Baccarani, M.; Cortes, J.; Pane, F.; Niederwieser, D.; Saglio, G.; Apperley, J.; Cervantes, F.; Deininger, M.; Gratwohl, A.; Guilhot, F.; Hochhaus, A.; Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Radich, J.; Simonsson, B.; Silver, R.; Goldman, J.; Hehlmann, R. |
| 2016 | Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients | Deininger, M.; Hodgson, J.; Shah, N.; Cortes, J.; Kim, D.; Nicolini, F.; Talpaz, M.; Baccarani, M.; Müller, M.; Li, J.; Parker, W.; Lustgarten, S.; Clackson, T.; Haluska, F.; Guilhot, F.; Kantarjian, H.; Soverini, S.; Hochhaus, A.; Hughes, T.; Rivera, V.; et al. |
| 2012 | Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia | Yin, O.; Giles, F.; Baccarani, M.; le Coutre, P.; Chiparus, O.; Gallagher, N.; Saglio, G.; Hughes, T.; Hochhaus, A.; Kantarjian, H.; Larson, R. |
| 2013 | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 | Baccarani, M.; Deininger, M.; Rosti, G.; Hochhaus, A.; Soverini, S.; Apperley, J.; Cervantes, F.; Clark, R.; Cortes, J.; Guilhot, F.; Hansen-Hjorth, H.; Hughes, T.; Kantarjian, H.; Kim, D.; Larson, R.; Lipton, J.; Mahon, F.; Martinelli, G.; Mayer, J.; Muller, M.; et al. |
| 2003 | Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia | O'Brien, S.; Guilhot, F.; Larson, R.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Lechner, K.; Nielsen, J.; Rousselot, P.; Reiffers, J.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J.; Kantarjian, H.; et al. |
| 2017 | Long-term outcomes of imatinib treatment for chronic myeloid leukemia | Hochhaus, A.; Larson, R.; Guilhot, F.; Radich, J.; Branford, S.; Hughes, T.; Baccarani, M.; Deininger, M.; Cervantes, F.; Fujihara, S.; Ortmann, C.; Menssen, H.; Kantarjian, H.; O'Brien, S.; Druker, B. |
| 2014 | Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study | Baccarani, M.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Mongay, L.; Mone, M.; Ortmann, C.; Kantarjian, H.; Radich, J.; Hughes, T.; Cortes, J.; Guilhot, F. |
| 2008 | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia | le Coutre, P.; Ottmann, O.; Giles, F.; Kim, D.; Cortes, J.; Gattermann, N.; Apperley, J.; Larson, R.; Abruzzese, E.; O'Brien, S.; Kuliczkowski, K.; Hochhaus, A.; Mahon, F.; Saglio, G.; Gobbi, M.; Kwong, Y.; Baccarani, M.; Hughes, T.; Martinelli, G.; Radich, J.; et al. |
| 2011 | Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results | Kantarjian, H.; Giles, F.; Bhalla, K.; Pinilla-Ibarz, J.; Larson, R.; Gattermann, N.; Ottmann, O.; Hochhaus, A.; Radich, J.; Saglio, G.; Hughes, T.; Martinelli, G.; Kim, D.; Shou, Y.; Gallagher, N.; Blakesley, R.; Baccarani, M.; Cortes, J.; le Coutre, P. |
| 2008 | Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia | Giles, F.; DeAngelo, D.; Baccarani, M.; Deininger, M.; Guilhot, F.; Hughes, T.; Radich, J.; Ottmann, O.; Cortes, J. |
| 2010 | Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study | Cortes, A.; Baccarani, M.; Guilhot, F.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Pasquini, R.; Goldberg, S.; Kalaycio, M.; Moiraghi, B.; Rowe, J.; Tothova, E.; de Souza, C.; Rudoltz, M.; Yu, R.; Krahnke, T.; Kantarjian, H.; Radich, J.; Hughes, T. |
| 2012 | Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial | Guilhot, F.; Hughes, T.; Cortes, J.; Druker, B.; Baccarani, M.; Gathmann, I.; Hayes, M.; Granvil, C.; Wang, Y. |
| 2016 | Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial | Lipton, J.; Chuah, C.; Guerci-Bresler, A.; Rosti, G.; Simpson, D.; Assouline, S.; Etienne, G.; Nicolini, F.; le Coutre, P.; Clark, R.; Stenke, L.; Andorsky, D.; Oehler, V.; Lustgarten, S.; Rivera, V.; Clackson, T.; Haluska, F.; Baccarani, M.; Cortes, J.; Guilhot, F.; et al. |
